Outcome of patients in CR at day +100 after HDT/ASCT included in the GEM2000 and GEM2005 < 65y trials. (A-B) TTP and OS for patients in CR versus those in less than CR at day +100 after HDT/ASCT. Broken lines in panel B indicate TTP and OS for patients who lost their CR status during the first year after HDT/ASCT (unsustained CR; n = 29 [12%]). (C-D), Landmark analysis for TTP and OS after day +100 after HDT/ASCT of patients (n = 110) in CR according to the pattern of FISH cytogenetics at baseline and immunophenotypic CR status at day +100 after HDT/ASCT.